Chair of the Investment Committee

Member of the Private Equity Investment Committee: Venture Capital, Growth Equity, Co-Investments, Secondaries, Middle Market and Large Buyouts California’s $490 billion pension fund serving more than 2 million members. Focused on leading CalPERS’ $60 billion private equity portfolio across all functions, including strategy, team management, and investment activities across primary, secondary, and co-investment opportunities globally

Member of the Global Private Equity and Special Opportunities Investment Committees$80 billion sovereign wealth fund with over $15 billion of assets under management in private equity and special opportunities. Dual mandates focused on developing (1) a diversified, global private equity portfolio and (2) a thematic, concentrated special opportunities portfolio across investment firm ownership stakes, co-investments and direct, non-control investments into operating companiesFY 2021 returns of 65%. One, three and five year net IRR returns of 40%, 25% and 21% respectively and 65% net IRR on direct and co-investments as of CYE20. Board observer: Codiak Biosciences (NSDQ: CDAK), Denali Therapeutics (NSDQ: DNLI) and Indigo Agriculture. Founding shareholder group in Vir Bio (NSDQ: VIR) and Sana Bio (NSDQ: SANA)

Member of the Global Investment Committee Primary and Direct Investments, Americas: New York Global private equity group with $13 billion of client assets under management. Led diligence on global partnership and direct investment opportunities in venture capital, leveraged buyouts, private credit, infrastructure and real estate

Private equity firm (GM spin-out) with $13 billion under management that invests in buyout, venture capital, real asset and distressed credit opportunities through primary partnerships, secondary acquisitions, and direct investments in companies

$10 billion multi-strategy investment firm focused on credit and special situations investments

Investment Banking

Investment Banking

Private Banking Investment Group